The Long-Term Effects of ADHD Medication
Why methylphenidate is the frontline treatment for ADHD.
Posted February 14, 2025 | Reviewed by Tyler Woods
This article was co-authored by Annika Angelo , M.S. and Nutrition Specialist, and Ludovico Saint Amour di Chanaz, Ph.D, and author of the ADHD User's Manual
Attention -Deficit/Hyperactivity Disorder ( ADHD ) is a neurodevelopmental condition wherein people experience issues with attention, hyperactivity, impulsivity, and executive function . The first line of treatment is often pharmacological. Stimulants, in particular, are the most prescribed medication for ADHD, and among stimulants, methylphenidate is the most commonly used.
ADHD medication was shown to aid in the management of ADHD; decreasing the intensity of symptoms, reducing the associated anxiety and depression , and aiding in day-to-day activities. Despite the large body of evidence showing this efficiency, medication has been widely criticized in many countries, mostly out of fear of the long-term effects of medication.
While there is evidence that long-term use of stimulant medication may indeed increase blood pressure and the risk of cardiovascular issues, there are also long-term positive effects that people seldom talk about. Here are a few of them:
ADHD medication is a first-line intervention because it decreases symptoms and leads to long-term benefits across several areas of life and health metrics. Despite these advantages, side effects have also been studied, such as an increased risk of cardiovascular issues. Additionally, not everyone reacts well to stimulant treatment.
While ADHD medication is not a miracle cure and other treatments and interventions for ADHD should be studied, it still makes for a qualitative intervention that to this day saves lives, and allows many individuals to grow and heal from their past. Some people will take it for a short time, as a crutch to look into other interventions and adaptations, while others may need it their whole life. Regardless of individual needs, ADHD medication and diagnosis should be accessible as it increases the quality of life of many individuals.
Zhang L, Li L, Andell P, Garcia-Argibay M, Quinn PD, D'Onofrio BM, Brikell I, Kuja-Halkola R, Lichtenstein P, Johnell K, Larsson H, Chang Z. Attention-Deficit/Hyperactivity Disorder Medications and Long-Term Risk of Cardiovascular Diseases. JAMA Psychiatry. 2024 Feb 1;81(2):178-187. doi: 10.1001/jamapsychiatry.2023.4294. PMID: 37991787; PMCID: PMC10851097.
Matochik JA, Nordahl TE, Gross M, Semple WE, King AC, Cohen RM, Zametkin AJ. Effects of acute stimulant medication on cerebral metabolism in adults with hyperactivity. Neuropsychopharmacology. 1993 Jun;8(4):377-86. doi: 10.1038/npp.1993.38. PMID: 8512624.
Akay AP, Resmi H, Güney SA, Erkuran HÖ, Özyurt G, Sargin E, Topuzoglu A, Tufan AE. Serum brain-derived neurotrophic factor levels in treatment-naïve boys with attention-deficit/hyperactivity disorder treated with methylphenidate: an 8-week, observational pretest-posttest study. Eur Child Adolesc Psychiatry. 2018 Jan;27(1):127-135. doi: 10.1007/s00787-017-1022-y. Epub 2017 Jul 14. PMID: 28710695.
Chang Z, Lichtenstein P, Halldner L, D'Onofrio B, Serlachius E, Fazel S, Långström N, Larsson H. Stimulant ADHD medication and risk for substance abuse. J Child Psychol Psychiatry. 2014 Aug;55(8):878-85. doi: 10.1111/jcpp.12164. Epub 2013 Oct 25. PMID: 25158998; PMCID: PMC4147667.
Levine SZ, Rotstein A, Kodesh A, Sandin S, Lee BK, Weinstein G, Schnaider Beeri M, Reichenberg A. Adult Attention-Deficit/Hyperactivity Disorder and the Risk of Dementia. JAMA Netw Open. 2023 Oct 2;6(10):e2338088. doi: 10.1001/jamanetworkopen.2023.38088. PMID: 37847497; PMCID: PMC10582792.
Man KKC, Coghill D, Chan EW, Lau WCY, Hollis C, Liddle E, Banaschewski T, McCarthy S, Neubert A, Sayal K, Ip P, Schuemie MJ, Sturkenboom MCJM, Sonuga-Barke E, Buitelaar J, Carucci S, Zuddas A, Kovshoff H, Garas P, Nagy P, Inglis SK, Konrad K, Häge A, Rosenthal E, Wong ICK. Association of Risk of Suicide Attempts With Methylphenidate Treatment. JAMA Psychiatry. 2017 Oct 1;74(10):1048-1055. doi: 10.1001/jamapsychiatry.2017.2183. PMID: 28746699; PMCID: PMC5710471.
Kim JH, Park S, Lee YJ. Systematic Review of Suicidal Behaviors Related to Methylphenidate and Atomoxetine in Patients With Attention Deficit Hyperactivity Disorder. Soa Chongsonyon Chongsin Uihak. 2023 Apr 1;34(2):125-132. doi: 10.5765/jkacap.220040. PMID: 37035791; PMCID: PMC10080256.
Share this post Facebook Bluesky Linkedin Email
There was a problem adding your email address. Please try again.
By submitting your information you agree to the Psychology Today Terms & Conditions and Privacy Policy
Ludovico Saint Amour di Chanaz, Ph.D., is a neuroscientist, neurodiversity advocate, and author of The ADHD User’s Manual.
Get the help you need from a therapist near you–a FREE service from Psychology Today.
This article is part of the Bringwise Psychology Journal — daily insights on human behavior, mental health, and personal growth.